Inhibition of tumor promoting signals by activation of SSTR2 and opioid receptors in human breast cancer cells

Cancer Cell International

Volumn 13, Issue 1, 2013, Pages

  Kharmate, Geetanjali ^a   Rajput, Padmesh S ^a   Lin, Yu Chen ^a   Kumar, Ujendra ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Breast cancer; Mitogen activated protein kinases; Opioid receptors and somatostatin receptor 2

Indexed keywords

DELTA OPIATE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KAPPA OPIATE RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MU OPIATE RECEPTOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN P53; SOMATOSTATIN RECEPTOR 2; SYNAPTOPHYSIN;

ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CANCER HORMONE THERAPY; CANCER INHIBITION; CELL CYCLE ARREST; CELL DEATH; CELL DIFFERENTIATION; CELL SURFACE; CELL SURVIVAL; CELLULAR DISTRIBUTION; COMPARATIVE STUDY; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME LOCALIZATION; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IMMUNOREACTIVITY; INTRACELLULAR SIGNALING; MOLECULAR SIZE; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

EID: 84884410674     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-13-93     Document Type: Article

References (61)

1. Ben-Shlomo A, Melmed S. Somatostatin agonists for treatment of acromegaly. Mol Cell Endocrinol 2008, 286(1-2):192-198. 2697610, 18191325.
2. Buscail L, Esteve J, Saint-Laurent N, Bertrand V, Reisine T, O'Carroll A, Bell GI, Schally AV, Vaysse N, Susini C. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Nat Acad Sci 1995, 92(5):1580-1584. 10.1073/pnas.92.5.1580, 42563, 7878022.
3. Buscail L, Vernejoul F, Faure P, Torrisani J, Susini C. Regulation of cell proliferation by somatostatin. Ann Endocrinol (Paris) 2002, 63(2 Pt 3):2S13-12S18.
4. Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P, Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Res Treat 2005, 92(2):175-186. 10.1007/s10549-005-2414-0, 15986128.
5. Prevost G, Hosford D, Thomas F. Receptors for somatostatin and somatostatin analogues in human breast tumors. Ann N Y Acad Sci 1994, 733:147-154. 10.1111/j.1749-6632.1994.tb17264.x, 7978862.
6. Murray RD, Kim K, Ren SG, Chelly M, Umehara Y, Melmed S. Central and peripheral actions of somatostatin on the growth hormone-IGF-I axis. J Clin Invest 2004, 114(3):349-356. 484973, 15286801.
7. Boccardo F, Amoroso D. Management of breast cancer: is there a role for somatostatin and its analogs?. Chemotherapy 2001, 47(Suppl. 2):62-77. 10.1159/000049162, 11275703.
8. Barrie R, Woltering EA, Hajarizadeh H, Mueller C, Ure T, Fletcher WS. Inhibition of angiogenesis by somatostatin and somatostatin-like compounds is structurally dependent. J Surg Res 1993, 55(4):446-450. 10.1006/jsre.1993.1167, 7692142.
9. Florio T, Morini M, Villa V, Arena S, Corsaro A, Thellung S, Culler MD, Pfeffer U, Noonan DM, Schettini G, et al. Somatostatin inhibits tumor angiogenesis and growth via somatostatin receptor-3-mediated regulation of endothelial nitric oxide synthase and mitogen-activated protein kinase activities. Endocrinology 2003, 144(4):1574-1584. 10.1210/en.2002-220949, 12639942.
10. Florio T, Thellung S, Arena S, Corsaro A, Spaziante R, Gussoni G, Acuto G, Giusti M, Giordano G, Schettini G. Somatostatin and its analog lanreotide inhibit the proliferation of dispersed human non-functioning pituitary adenoma cells in vitro. Eur J Endocrinol 1999, 141(4):396-408. 10.1530/eje.0.1410396, 10526255.
11. Liu AMF, Wong YH. Activation of nuclear factor ΰB by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves GÎ ± 14 and multiple signaling components. J Biol Chem 2005, 280(41):34617-34625. 10.1074/jbc.M504264200, 16115892.
12. Reubi JC, Waser B, Foekens JA, Klijn JGM, Lamberts SWJ, Laissue J. Somatostatin receptor incidence and distribution in breast cancer using receptor autoradiography: relationship to egf receptors. Intnl J Can 1990, 46(3):416-420.
13. Watt HL, Kharmate GD, Kumar U. Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. Cell Signal 2009, 21(3):428-439. 10.1016/j.cellsig.2008.11.012, 19070659.
14. Vikic-Topic S, Raisch KP, Kvols LK, Vuk-Pavlovic S. Expression of somatostatin receptor subtypes in breast carcinoma, carcinoid tumor, and renal cell carcinoma. J Clin Endocrinol Metab 1995, 80(10):2974-2979. 10.1210/jc.80.10.2974, 7559883.
15. Pfeiffer M, Koch T, Schroder H, Laugsch M, Hollt V, Schulz S. Heterodimerization of somatostatin and opioid receptors cross-modulates phosphorylation, internalization, and desensitization. J Biol Chem 2002, 277(22):19762-19772. 10.1074/jbc.M110373200, 11896051.
16. He Y, Yuan X-M, Lei P, Wu S, Xing W, Lan X-L, Zhu H-F, Huang T, Wang G-B, An R, et al. The antiproliferative effects of somatostatin receptor subtype 2 in breast cancer cells. Acta Pharmacol Sin 2009, 30(7):1053-1059. 10.1038/aps.2009.59, 19575008.
17. Bousquet C, Guillermet-Guibert J, Saint-Laurent N, Archer-Lahlou E, Lopez F, Fanjul M, Ferrand A, Fourmy D, Pichereaux C, Monsarrat B, et al. Direct binding of p85 to sst2 somatostatin receptor reveals a novel mechanism for inhibiting PI3K pathway. Embo J 2006, 25(17):3943-3954. 10.1038/sj.emboj.7601279, 1560358, 16917505.
18. Grant M, Kumar U. The role of G-proteins in the dimerisation of human somatostatin receptor types 2 and 5. Regul Pept 2009, 159(1-3):3-8.
19. Reardon DB, Dent P, Wood SL, Kong T, Sturgill TW. Activation in vitro of somatostatin receptor subtypes 2, 3, or 4 stimulates protein tyrosine phosphatase activity in membranes from transfected Ras-transformed NIH 3T3 cells: coexpression with catalytically inactive SHP-2 blocks responsiveness. Mol Endocrinol 1997, 11(8):1062-1069. 10.1210/me.11.8.1062, 9212054.
20. Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Role of somatostatin receptor 1 and 5 on epidermal growth factor receptor mediated signaling. Biochim Biophys Acta 2011, 1813(6):1172-1189. 10.1016/j.bbamcr.2011.03.006, 21419811.
21. Kharmate G, Rajput PS, Watt HL, Somvanshi RK, Chaudhari N, Qiu X, Kumar U. Dissociation of epidermal growth factor receptor and ErbB2 heterodimers in the presence of somatostatin receptor 5 modulate signaling pathways. Endocrinology 2011, 152(3):931-945. 10.1210/en.2010-0940, 21190959.
22. Foekens JA, Portengen H, van Putten WLJ, Trapman A, Reubi JC, Alexieva-Figusch J, Klijn JGM. Prognostic value of receptors for insulin-like growth factor 1, somatostatin, and epidermal growth factor in human breast cancer. Cancer Res 1989, 49:7002-7009.
23. Alroy I, Yarden Y. The ErbB signaling network in embryogenesis and oncogenesis: signal diversification through combinatorial ligand-receptor interactions. FEBS Lett 1997, 410(1):83-86. 10.1016/S0014-5793(97)00412-2, 9247128.
24. Bacus SS, Gudkov AV, Esteva FJ, Yarden Y. Expression of erbB receptors and their ligands in breast cancer: implications to biological behavior and therapeutic response. Breast Dis 2000, 11:63-75.
25. Hatzoglou A, Ouafik LH, Bakogeorgou E, Thermos K, Castanas E. Morphine cross-reacts with somatostatin receptor SSTR2 in the T47D human breast cancer cell line and decreases cell growth. Cancer Res 1995, 55(23):5632-5636.
26. Reisine T, Bell GI. Molecular biology of opioid receptors. Trends Neurosci 1993, 16(12):506-510. 10.1016/0166-2236(93)90194-Q, 7509520.
27. Panagiotou S, Bakogeorgou E, Papakonstanti E, Hatzoglou A, Wallet F, Dussert C, Stournaras C, Martin P-M, Castanas E. Opioid agonists modify breast cancer cell proliferation by blocking cells to the G2/M phase of the cycle: involvement of cytoskeletal elements. J Cell Biochem 1999, 73(2):204-211. 10.1002/(SICI)1097-4644(19990501)73:2<204::AID-JCB6>3.0.CO;2-V, 10227383.
28. Persson AI, Thorlin T, Bull C, Zarnegar P, Ekman R, Terenius L, Eriksson PS. Mu- and delta-opioid receptor antagonists decrease proliferation and increase neurogenesis in cultures of rat adult hippocampal progenitors. Eur J Neurosci 2003, 17(6):1159-1172. 10.1046/j.1460-9568.2003.02538.x, 12670304.
29. Zagon IS, McLaughlin PJ, Goodman SR, Rhodes RE. Opioid receptors and endogenous opioids in diverse human and animal cancers. J Natl Cancer Inst 1987, 79(5):1059-1065.
30. Scopsi L, Balslev E, Brunner N, Poulsen HS, Andersen J, Rank F, Larsson LI. Immunoreactive opioid peptides in human breast cancer. Am J Pathol 1989, 134(2):473-479. 1879588, 2464945.
31. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 1996, 296(2):199-207. 10.1016/0014-2999(95)00703-2, 8838457.
32. Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 1990, 50(8):2234-2238.
33. Devi LA. Heterodimerization of G-protein-coupled receptors: pharmacology, signaling and trafficking. Trends Pharmacol Sci 2001, 22(10):532-537. 10.1016/S0165-6147(00)01799-5, 11583811.
34. Rocheville M, Lange DC, Kumar U, Patel SC, Patel RC, Patel YC. Receptors for dopamine and somatostatin: formation of hetero-oligomers with enhanced functional activity. Science 2000, 288(5463):154-157. 10.1126/science.288.5463.154, 10753124.
35. Baragli A, Alturaihi H, Watt HL, Abdallah A, Kumar U. Heterooligomerization of human dopamine receptor 2 and somatostatin receptor 2: co-immunoprecipitation and fluorescence resonance energy transfer analysis. Cell Signal 2007, 19(11):2304-2316. 10.1016/j.cellsig.2007.07.007, 17706924.
36. Grant M, Collier B, Kumar U. Agonist-dependent dissociation of human somatostatin receptor 2 dimers: a role in receptor trafficking. J Biol Chem 2004, 279(35):36179-36183. 10.1074/jbc.M407310200, 15231824.
37. Patel RC, Kumar U, Lamb DC, Eid JS, Rocheville M, Grant M, Rani A, Hazlett T, Patel SC, Gratton E, et al. Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc Natl Acad Sci USA 2002, 99(5):3294-3299. 10.1073/pnas.042705099, 122512, 11880655.
38. Jaquet P, Gunz G, Saveanu A, Dufour H, Taylor J, Dong J, Kim S, Moreau JP, Enjalbert A, Culler MD. Efficacy of chimeric molecules directed towards multiple somatostatin and dopamine receptors on inhibition of GH and prolactin secretion from GH-secreting pituitary adenomas classified as partially responsive to somatostatin analog therapy. Eur J Endocrinol 2005, 153(1):135-141. 10.1530/eje.1.01950, 15994755.
39. Saveanu A, Gunz G, Guillen S, Dufour H, Culler MD, Jaquet P. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas. Neuroendocrinology 2006, 83(3-4):258-263.
40. Saveanu A, Lavaque E, Gunz G, Barlier A, Kim S, Taylor JE, Culler MD, Enjalbert A, Jaquet P. Demonstration of enhanced potency of a chimeric somatostatin-dopamine molecule, BIM-23A387, in suppressing growth hormone and prolactin secretion from human pituitary Somatotroph adenoma cells. J Clin Endocrinol Metab 2002, 87(12):5545-5552. 10.1210/jc.2002-020934, 12466351.
41. Rivera JA, Alturaihi H, Kumar U. Differential regulation of somatostatin receptors 1 and 2 mRNA and protein expression by tamoxifen and estradiol in breast cancer cells. J Carcinog 2005, 4(1):10. 10.1186/1477-3163-4-10, 1184089, 16018813.
42. Xu Y, Berelowitz M, Bruno JF. Dexamethasone regulates somatostatin receptor subtype messenger ribonucleic acid expression in rat pituitary GH4C1 cells. Endocrinology 1995, 136(11):5070-5075. 10.1210/en.136.11.5070, 7588243.
43. Xu Y, Song J, Berelowitz M, Bruno JF. Estrogen regulates somatostatin receptor subtype 2 messenger ribonucleic acid expression in human breast cancer cells. Endocrinology 1996, 137(12):5634-5640. 10.1210/en.137.12.5634, 8940394.
44. Kumar U. Expression of somatostatin receptor subtypes (SSTR1-5) in alzheimer's disease brain: an immunohistochemical analysis. Neuroscience 2005, 134:525-538. 10.1016/j.neuroscience.2005.04.001, 15961235.
45. Kumar U. Colocalization of somatostatin receptor subtypes (SSTR1-5) with somatostatin, NADPH-diaphorase (NADPH-d), and tyrosine hydroxylase in the rat hypothalamus. J Comp Neurol 2007, 504(2):185-205. 10.1002/cne.21444, 17626271.
46. Enslen H, Brancho DM, Davis RJ. Molecular determinants that mediate selective activation of p38 MAP kinase isoforms. Embo J 2000, 19(6):1301-1311. 10.1093/emboj/19.6.1301, 305671, 10716930.
47. Zarubin T, Han J. Activation and signaling of the p38 MAP kinase pathway. Cell Res 2005, 15(1):11-18. 10.1038/sj.cr.7290257, 15686620.
48. Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, Linn SC, Gonzalez-Angulo AM, Stemke-Hale K, Hauptmann M, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007, 12(4):395-402. 10.1016/j.ccr.2007.08.030, 17936563.
49. Esteva FJ, Guo H, Zhang S, Santa-Maria C, Stone S, Lanchbury JS, Sahin AA, Hortobagyi GN, Yu D. PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 2010, 177(4):1647-1656. 10.2353/ajpath.2010.090885, 2947262, 20813970.
50. López-Knowles E, O'Toole SA, McNeil CM, Millar EKA, Qiu MR, Crea P, Daly RJ, Musgrove EA, Sutherland RL. PI3K pathway activation in breast cancer is associated with the basal-like phenotype and cancer-specific mortality. Int J Cancer 2009, 126(5):1121-1131.
51. Kallergi G, Agelaki S, Kalykaki A, Stournaras C, Mavroudis D, Georgoulias V. Phosphorylated EGFR and PI3K/Akt signaling kinases are expressed in circulating tumor cells of breast cancer patients. Br Cancer Res 2008, 10(5):R80.
52. Gomes I, Jordan BA, Gupta A, Rios C, Trapaidze N, Devi LA. G protein coupled receptor dimerization: implications in modulating receptor function. J Mol Med 2001, 79(5-6):226-242.
53. Nebreda AR, Porras A. p38 MAP kinases: beyond the stress response. Trends Biochem Sci 2000, 25(6):257-260. 10.1016/S0968-0004(00)01595-4, 10838561.
54. Campbell RA, Bhat-Nakshatri P, Patel NM, Constantinidou D, Ali S, Nakshatri H. Phosphatidylinositol 3-kinase/AKT-mediated activation of estrogen receptor α. J Biol Chem 2001, 276(13):9817-9824. 10.1074/jbc.M010840200, 11139588.
55. Sabbatini P, McCormick F. Phosphoinositide 3-OH kinase (PI3K) and PKB/Akt delay the onset of p53-mediated, transcriptionally dependent apoptosis. J Biol Chem 1999, 274(34):24263-24269. 10.1074/jbc.274.34.24263, 10446202.
56. Zheng L, Ren JQ, Li H, Kong ZL, Zhu HG. Downregulation of wild-type p53 protein by HER-2/neu mediated PI3K pathway activation in human breast cancer cells: its effect on cell proliferation and implication for therapy. Cell Res 2004, 14(6):497-506. 10.1038/sj.cr.7290253, 15625017.
57. Gan HK, Walker F, Burgess AW, Rigopoulos A, Scott AM, Johns TG. The epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor AG1478 increases the formation of inactive Untethered EGFR dimers. J Biol Chem 2007, 282(5):2840-2850.
58. Davidson NE, Gelmann EP, Lippman ME, Dickson RB. Epidermal growth factor receptor gene expression in estrogen receptor-positive and negative human breast cancer cell lines. Mol Endocrinol 1987, 1(3):216-223. 10.1210/mend-1-3-216, 3502607.
59. Lichtner RB, Menrad A, Sommer A, Klar U, Schneider MR. Signaling-inactive epidermal growth factor receptor/ligand complexes in intact carcinoma cells by quinazoline tyrosine kinase inhibitors. Cancer Res 2001, 61(15):5790-5795.
60. Narayan M, Wilken JA, Harris LN, Baron AT, Kimbler KD, Maihle NJ. Trastuzumab-induced HER reprogramming in " resistant" breast carcinoma cells. Cancer Res 2009, 69(6):2191-2194. 10.1158/0008-5472.CAN-08-1056, 19276389.
61. Williams G, Ball J, Bloom S, Joplin GF. Improvement in headache associated with prolactinoma during treatment with a somatostatin analogue: an " N of 1" study. N Engl J Med 1986, 315(18):1166-1167.